Anthony Saleh

Anthony Saleh

Company: MiRecule Inc.

Job title: CEO


MC-30, a Targeted MicroRNA Therapy Inhibiting RTK Signalling and Drug Resistance in Head and Neck Cancer 1:15 pm

miR-30-5p is a critical tumor suppressor in a subset of head and neck cancers targeting multiple receptor tyrosine kinase pathways Genetic loss is associated with increased recurrence and poor outcomes MC-30 a novel targeted therapy mimicking the natural miR-30 gene can reduce drug resistance and may extend progression-free survivalRead more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.